Urological Oncology: Prostate Cancer

The document discussed the relationship between male pattern baldness and prostate cancer risk, highlighting findings from various studies. One study indicated that dihydrotestosterone levels were linked to survival rates in prostate cancer detected through screening over a 15-year follow-up period. Another study found that a low-activity V89L variant in the SRD5A2 gene was associated with an increased risk of aggressive prostate cancer, potentially explaining adverse effects in chemoprevention trials using 5-alpha-reductase inhibitors. Additionally, there was speculation that early baldness might protect against prostate cancer by increasing skin exposure to ultraviolet radiation. The document also mentioned the use of dutasteride (Avodart) for prostate cancer prevention, referencing a study from the New England Journal of Medicine in 2010.